Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2568 - A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Lothar Häberle

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

L. Häberle1, R. Erber2, P. Gaß1, A. Hein1, S.M. Jud1, H. Langemann1, C. Rauh1, C.C. Hack1, R. Schulz-Wendtland3, A. Hartmann2, M.W. Beckmann1, M.P. Lux1, P.A. Fasching1

Author affiliations

  • 1 Department Of Gynecology And Obstetrics, Erlangen University Hospital, 91054 - Erlangen/DE
  • 2 Institute Of Pathology, Erlangen University Hospital, 91054 - Erlangen/DE
  • 3 Institute Of Radiology, Erlangen University Hospital, 91054 - Erlangen/DE
More

Resources

Abstract 2568

Background

Pathological complete response (pCR) is an established surrogate marker for survival in breast cancer (BC) patients treated with neoadjuvant chemotherapy. Prediction of pCR based on clinical information available at biopsy, particularly the biomarkers estrogen receptor (ER), progesterone receptor (PgR) and Ki-67 expression, might assist in the identification of patients who benefit of preoperative chemotherapy. Although biomarker assessment is mostly reported as the percentage of positively stained cells with values from 0 to 100%, cut-off points are used to classify patients into groups. Aim of this study was to examine established cut-off points and to develop a prediction tool estimating a patient’s pCR likelihood obtained from clinical predictors and these biomarkers as assessed during clinical routine or categorically with established or newfound thresholds.

Methods

This study included all HER2-negative BC patients from one German institution treated with neoadjuvant chemotherapy from 2002 to 2017, having complete observations (N = 829). Various logistic regression models for predicting pCR which differ from each other by the usage of the biomarkers were set-up: (M1) continuous biomarkers from 0 to 100% as assessed during clinical routine, (M2) categorical (positive/negative) biomarkers with established thresholds, (M3) categorical biomarkers with newfound thresholds. Prediction accuracy (e.g., AUC) was assessed using cross-validation.

Results

A total of 163 (19.7%) patients achieved a pCR. The optimal cut-off points for ER, PgR and Ki-67 were 30%, 10% and 35%, respectively. The prediction model M1 with continuous biomarkers was more precise (cross-validated AUC, 0.863) than the prediction models M2 and M3 (both 0.854). The most accurate model M1 had a sensitivity of 0.80 at a specificity of 0.78. Beside these biomarkers, a patient’s likelihood of achieving a pCR depended on age at diagnosis, clinical tumor stage and grading.

Conclusions

Using biomarkers as continuous variables yielded more precise predictions than when used categorically. Therapy decisions should base on predicted pCR probabilities obtained from multivariable prediction models rather than single biomarker values.

Clinical trial identification

Legal entity responsible for the study

Erlangen University Hospital, Erlangen.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

A. Hartmann: Personal fees: AstraZeneca, BMS, MSD; Grants: Biontech, Nanostring; Personal fees and non-financial support: Roche, Sysmex; Grants: Janssen, Cepheid outside the submitted work. P.A. Fasching: Grants and personal fees: Novartis; Personal fees: Pfizer, Roche, Teva, Celgene; Grants: Biontech, outside the submitted work. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings